ALPHA TAU MEDICAL LTD (DRTS) Stock Fundamental Analysis

NASDAQ:DRTS • IL0011839383

7.76 USD
-0.17 (-2.14%)
At close: Feb 27, 2026
7.8 USD
+0.04 (+0.52%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall DRTS gets a fundamental rating of 2 out of 10. We evaluated DRTS against 184 industry peers in the Health Care Equipment & Supplies industry. While DRTS seems to be doing ok healthwise, there are quite some concerns on its profitability. DRTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year DRTS has reported negative net income.
  • In the past year DRTS has reported a negative cash flow from operations.
  • In the past 5 years DRTS always reported negative net income.
  • DRTS had a negative operating cash flow in each of the past 5 years.
DRTS Yearly Net Income VS EBIT VS OCF VS FCFDRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • DRTS's Return On Assets of -31.73% is in line compared to the rest of the industry. DRTS outperforms 40.54% of its industry peers.
  • The Return On Equity of DRTS (-40.64%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -31.73%
ROE -40.64%
ROIC N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
DRTS Yearly ROA, ROE, ROICDRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • DRTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRTS Yearly Profit, Operating, Gross MarginsDRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • DRTS has more shares outstanding than it did 1 year ago.
  • DRTS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for DRTS is higher compared to a year ago.
DRTS Yearly Shares OutstandingDRTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
DRTS Yearly Total Debt VS Total AssetsDRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 13.94 indicates that DRTS is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 13.94, DRTS belongs to the best of the industry, outperforming 93.51% of the companies in the same industry.
  • A Debt/Equity ratio of 0.07 indicates that DRTS is not too dependend on debt financing.
  • The Debt to Equity ratio of DRTS (0.07) is better than 66.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 13.94
ROIC/WACCN/A
WACCN/A
DRTS Yearly LT Debt VS Equity VS FCFDRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • DRTS has a Current Ratio of 10.52. This indicates that DRTS is financially healthy and has no problem in meeting its short term obligations.
  • DRTS has a Current ratio of 10.52. This is amongst the best in the industry. DRTS outperforms 92.43% of its industry peers.
  • DRTS has a Quick Ratio of 10.52. This indicates that DRTS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of DRTS (10.52) is better than 95.14% of its industry peers.
Industry RankSector Rank
Current Ratio 10.52
Quick Ratio 10.52
DRTS Yearly Current Assets VS Current LiabilitesDRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for DRTS have decreased strongly by -20.93% in the last year.
EPS 1Y (TTM)-20.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 27.08% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.22%
EPS Next 2Y-4.36%
EPS Next 3Y5.27%
EPS Next 5Y27.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DRTS. In the last year negative earnings were reported.
  • Also next year DRTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRTS Price Earnings VS Forward Price EarningsDRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRTS Per share dataDRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.36%
EPS Next 3Y5.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DRTS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALPHA TAU MEDICAL LTD

NASDAQ:DRTS (2/27/2026, 8:00:02 PM)

After market: 7.8 +0.04 (+0.52%)

7.76

-0.17 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-20
Earnings (Next)03-05
Inst Owners2.52%
Inst Owner Change22.55%
Ins Owners16.16%
Ins Owner ChangeN/A
Market Cap661.62M
Revenue(TTM)N/A
Net Income(TTM)-35.20M
Analysts86
Price Target8.41 (8.38%)
Short Float %1.15%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-11.55%
Max EPS beat(2)7.55%
EPS beat(4)2
Avg EPS beat(4)2.35%
Min EPS beat(4)-11.55%
Max EPS beat(4)18.47%
EPS beat(8)6
Avg EPS beat(8)11.12%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.64
P/tB 7.64
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS1.02
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.73%
ROE -40.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 495.91%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.52
Quick Ratio 10.52
Altman-Z 13.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)296.97%
Cap/Depr(5y)1091.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-16.22%
EPS Next 2Y-4.36%
EPS Next 3Y5.27%
EPS Next 5Y27.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.77%
EBIT Next 3Y1.57%
EBIT Next 5YN/A
FCF growth 1Y-39.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.9%
OCF growth 3YN/A
OCF growth 5YN/A

ALPHA TAU MEDICAL LTD / DRTS FAQ

What is the fundamental rating for DRTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRTS.


What is the valuation status for DRTS stock?

ChartMill assigns a valuation rating of 0 / 10 to ALPHA TAU MEDICAL LTD (DRTS). This can be considered as Overvalued.


What is the profitability of DRTS stock?

ALPHA TAU MEDICAL LTD (DRTS) has a profitability rating of 1 / 10.


Can you provide the financial health for DRTS stock?

The financial health rating of ALPHA TAU MEDICAL LTD (DRTS) is 6 / 10.


Can you provide the expected EPS growth for DRTS stock?

The Earnings per Share (EPS) of ALPHA TAU MEDICAL LTD (DRTS) is expected to decline by -16.22% in the next year.